Capex

Otitis Externa, Uveitis, Perianal erythema + 30 more

Treatment

3 FDA approvals

20 Active Studies for Capex

What is Capex

Fluocinolone acetonide

The Generic name of this drug

Treatment Summary

Fluocinolone acetonide is a steroid used in skin medications and implantable devices. It helps reduce inflammation and has been studied for its use in medical implants. In 2016, the FDA approved a device containing fluocinolone acetonide developed by Taro Pharmaceuticals.

Neo-Synalar

is the brand name

image of different drug pills on a surface

Capex Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Neo-Synalar

Fluocinolone acetonide

1963

93

Approved as Treatment by the FDA

Fluocinolone acetonide, otherwise called Neo-Synalar, is approved by the FDA for 3 uses like Chronic Uveitis and Uveitis .

Chronic Uveitis

Uveitis

Uveitis

Effectiveness

How Capex Affects Patients

Fluocinolone acetonide is a medication that works by reducing inflammation and narrowing blood vessels. It is given as an implant in the eye to treat uveitis, a condition that causes inflammation. Studies have found that it can reduce the recurrence of uveitis flares by two times compared to patients who did not take it, and it can also cause a slight increase in eye pressure. It is important to monitor eye pressure while taking fluocinolone acetonide.

How Capex works in the body

Fluocinolone acetonide is a corticosteroid that reduces inflammation by preventing the release of certain molecules that cause swelling and irritation. It does this by binding to the glucocorticoid receptor, which then helps to create proteins that block the release of arachidonic acid - the precursor of inflammatory molecules like prostaglandins and leukotrienes.

When to interrupt dosage

The proposed dose of Capex is contingent upon the recognized illness, including Hemorrhoids, Perianal erythema and Itch. The quantity of dosage is contingent upon the technique of application (e.g. Kit or Emulsion - Topical) outlined in the table beneath.

Condition

Dosage

Administration

Pressure Ulcer

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Conjunctivitis, Bacterial

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Skin Inflammation caused by Bacterial Infections

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Diabetic Macular Edema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Postoperative Care

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Eczema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Dermatitis, Seborrheic

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Externa

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Uveitis

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Otitis Media

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Chronic disease

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Surgery; Ear

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

postoperative treatment

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Ear structure

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Wound Infection

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Perianal erythema

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Scab

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Itching

, 0.0001 mg/mg, 0.1 mg/mL, 0.00025 mg/mg, 0.11 mg/mL, 0.011 mg/mL, 0.0011 mg/mL, 0.01 %, 0.59 mg, 0.025 %, 0.19 mg, 0.0001 mg/mL, 0.25 mg/mL, 1.0 mg/mg, 0.18 mg, 0.625 mg/mL, 0.000003 mg/mg

, Topical, Cream, Cream - Topical, Ointment - Topical, Ointment, Solution, Solution - Topical, Kit, Oil, Oil - Topical, Auricular (otic), Oil - Auricular (otic), Kit - Topical, Solution - Auricular (otic), Shampoo, Shampoo - Topical, Intravitreal, Implant, Gel - Topical, Gel, Emulsion - Topical, Emulsion, Implant - Intravitreal, Intraocular, Implant - Intraocular, Solution / drops, Solution / drops - Auricular (otic)

Warnings

Capex Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

Mycoses

Do Not Combine

External auditory canal structure

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluocinolone Acetonide may interact with conjunctiva

There are 20 known major drug interactions with Capex.

Common Capex Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Fluocinolone acetonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abetimus.

Capex Toxicity & Overdose Risk

Studies have not been done to see if fluocinolone acetonide has potential to cause cancer or fertility problems. However, other forms of corticosteroids have been linked to genetic damage, and the Ames test and mouse lymphoma TK assay have shown that this does not apply to fluocinolone acetonide.

image of a doctor in a lab doing drug, clinical research

Capex Novel Uses: Which Conditions Have a Clinical Trial Featuring Capex?

97 active trials are currently assessing the potential of Capex to mitigate Atopic Dermatitis, Otitis Media and Otitis Externa.

Condition

Clinical Trials

Trial Phases

Hemorrhoids

1 Actively Recruiting

Not Applicable

Perianal erythema

0 Actively Recruiting

Eczema

0 Actively Recruiting

Blister

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

Psoriasis of the scalp

1 Actively Recruiting

Phase 4

Otitis

3 Actively Recruiting

Not Applicable

Hemorrhoids

0 Actively Recruiting

Scab

0 Actively Recruiting

Ear structure

0 Actively Recruiting

Skin

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

Fissure in Ano

0 Actively Recruiting

Postoperative Care

5 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable

Wound Infection

0 Actively Recruiting

Skin Inflammation caused by Bacterial Infections

0 Actively Recruiting

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Conjunctivitis, Bacterial

0 Actively Recruiting

Coinfection

0 Actively Recruiting

Chronic disease

0 Actively Recruiting

Patient Q&A Section about capex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you calculate CapEx?

"In order to calculate capital expenditures, you will need the financial statements from your company from the past two years. To get this number, take the fixed assets and subtract the accumulated depreciation. Then, add the total depreciation."

Answered by AI

Is CapEx an asset?

"A capital expenditure is recorded as an asset on a company's balance sheet and is then charged to expense over the useful life of the asset using depreciation."

Answered by AI

What is CapEx and OpEx?

"OpEx, on the other hand, are the expenses incurred from normal business operations, such as labor, rent, and utilities.

A company's capital expenditures are its major, long-term expenses for things like physical assets, while operating expenses are the day-to-day expenses incurred from normal business operations."

Answered by AI

What is an example of CapEx?

"Examples of capital expenditure (CapEx) items might include a new printing press or a fleet of servers for a data center. These items are significant expenses that will provide value for many years to come and can therefore be capitalized over an extended period. Other examples of CapEx include capital leases."

Answered by AI

Clinical Trials for Capex

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of University of California, Los Angeles in Los Angeles, United States.

Hemorrhoidal Artery Embolization for Hemorrhoids

18 - 90
All Sexes
Los Angeles, CA

Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.

Recruiting
Has No Placebo

University of California, Los Angeles

Lucas Cusumano, MD

Have you considered Capex clinical trials?

We made a collection of clinical trials featuring Capex, we think they might fit your search criteria.
Go to Trials
Image of The University of Alabama at Birmingham in Birmingham, United States.

Octreotide for Diabetic Macular Edema

18 - 90
All Sexes
Birmingham, AL

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential therapeutic benefits in proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). This study thus seeks to determine the efficacy and safety of intranasal DDM-octreotide in the treatment of diabetic macula edema in individuals that are considered to be refractory to the current therapeutic options.

Phase 1
Waitlist Available

The University of Alabama at Birmingham

Maria Grant, MD, FARVO

Image of Associated Retinal Consultants PC in Phoenix, United States.

RO7446603 + Aflibercept/Faricimab for Diabetic Macular Edema

18+
All Sexes
Phoenix, AZ

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.

Phase 1 & 2
Recruiting

Associated Retinal Consultants PC (+70 Sites)

Clinical Trials

Genentech, Inc.

Image of Retinal Consultants of AZ, Ltd in Peoria, United States.

RO7497372 for Diabetic Macular Edema

18+
All Sexes
Peoria, AZ

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

Phase 1
Waitlist Available

Retinal Consultants of AZ, Ltd (+36 Sites)

Clinical Trials

Genentech, Inc.

Have you considered Capex clinical trials?

We made a collection of clinical trials featuring Capex, we think they might fit your search criteria.
Go to Trials
Image of University of Virginia in Charlottesville, United States.

Methadone vs Remifentanil for Pain in Craniotomy Surgery

18 - 65
All Sexes
Charlottesville, VA

Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.

Phase < 1
Waitlist Available

University of Virginia

Image of Scottsdale, Arizona in Scottsdale, United States.

EYE201 for Eye Conditions

18+
All Sexes
Scottsdale, AZ

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.

Phase 1 & 2
Recruiting

Scottsdale, Arizona (+25 Sites)

EyeBiotech Ltd.

Have you considered Capex clinical trials?

We made a collection of clinical trials featuring Capex, we think they might fit your search criteria.
Go to Trials